RxDoctor Payments Data

John Nail

Optometrist · Columbus, MSNPI 1174878052

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.2%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. Johnson & Johnson Vision Care, Inc. accounts for 62.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $1,798 and has fallen 93.5% since, to $117 in 2025.

$2,915in general payments, 2019–2025

Across 55 payments — averaging $53.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Bausch & Lomb Americas Inc.$281
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$215
  • Alcon$158
  • Optos, Inc.$150
  • Carl Zeiss Meditec, Inc.$76
  • plus $204 from 5 others

What the payments were for

  • Consulting fees$1,61055%
  • Food & beverage$1,15540%
  • Entertainment$1505%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,915 in reported general payments places this provider in the 85th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$139,031
Medicare patients
770
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost41$18,868
RestasisCyclosporine21$17,010
Travoprost32$5,983
Prednisolone Acetate120$3,842
CombiganBrimonidine Tartrate/Timolol11$3,207
SimbrinzaBrinzolamide/Brimonidine Tart14$2,821
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$2,813
Latanoprost202$1,680
Brimonidine Tartrate66$1,247
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat77$1,230
Doxycycline Monohydrate83$861
Timolol Maleate61$521
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$476
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha47$443
Dorzolamide Hcl20$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$158$2,82114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →